Background The coronavirus disease 2019 (COVID-19) caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to plague the world. While …

Vaccines and drugs have helped reduce disease severity and blunt the spread of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, ongoing virus …

The main protease (Mpro) of SARS-CoV-2 is essential for viral replication and has been the
focus of many drug discovery efforts since the start of the COVID-19 pandemic. Nirmatrelvir …

The rapid global spread of the SARS-CoV-2 virus facilitated the development of novel direct-
acting antiviral agents (DAAs). The papain-like protease (PLpro) has been proposed as one …

Botanical natural products have been widely consumed for their purported usefulness
against COVID-19. Here, six botanical species from multiple sources and 173 isolated …

Three directly acting antivirals (DAAs) demonstrated substantial reduction in COVID-19
hospitalizations and deaths in clinical trials. However, these agents did not completely …

As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve,
mutations arise that will allow the virus to evade immune defenses and therapeutics. Assays …

The main proteinase (Mpro), or 3CLpro, is a critical enzyme in the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) lifecycle and is responsible for breaking down and …

Viral helicases are promising targets for the development of antiviral therapies. Given their
vital function of unwinding double-stranded nucleic acids, inhibiting them blocks the viral …

Identification of host determinants of coronavirus infection informs mechanisms of
pathogenesis and may provide novel therapeutic targets. Here, we demonstrate that the …